Q-omics provides the consensus-scored DCBLD1 profile across patient tissues and cancer cell-line models. DCBLD1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DCBLD1 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, DCBLD1 RNA expression shows 19,166 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, HNSC, and UVM as cancer lineages where DCBLD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DCBLD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DCBLD1 survival associations across molecular data types. DCBLD1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DCBLD1 RNA expression–survival associations across cancer types. High DCBLD1 expression shows unfavorable associations in KIRP, MESO, HNSC, CESC, LGG and LUSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DCBLD1 RNA expression.
This table summarizes DCBLD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for DCBLD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DCBLD1 shows higher tumor expression in HNSC, BLCA, COAD, STAD, BRCA and KIRC. The HNSC box plot shows higher DCBLD1 RNA expression in tumor versus normal tissue (log2 FC = +2.341, t-test p < 0.001).
This table shows molecular features associated with DCBLD1 in patient tissues and cancer cell lines. In patient samples, DCBLD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DCBLD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BONE.
